Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
about
Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female miceApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiencyMaternal undernutrition programmes atherosclerosis in the ApoE*3-Leiden mouseIn the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men.Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study.Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity.Hypercholesterolemia impairs reactive hyperemic vasodilation of 2A but not 3A arterioles in mouse cremaster muscle.ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.The Use of L-sIDOL Transgenic Mice as a Murine Model to Study Hypercholesterolemia and Atherosclerosis.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
P2860
Q33992107-91871F79-9480-4202-9451-74088A3DE521Q35751146-A5C3240B-01A6-45B1-82E9-F5CAD7EAEB2AQ36558367-055AC4FA-31C8-466F-B466-BBACC358B21FQ37161229-2AD14D75-25E9-417E-92CF-6F0821E0C6AEQ37361432-31E17C95-B78D-4745-80A8-CFABED493F66Q40606150-D6C1C651-FD10-4A11-A252-7A4196A2F8F3Q42378083-B93821DE-C81D-468A-B54F-ECDF3BD563D7Q44063114-74A7818B-D0EF-4A86-A32D-834D372AD5AFQ45270099-FA922273-EFD3-465B-8CCF-5DB725007296Q45285417-23DE9ABE-AF07-4B86-8FA5-A63B3F48AE5CQ46466019-08E5D2FD-6757-4037-A50C-2C3D8F2CC92CQ47877816-6642157C-5906-4B99-B9E4-0214B3E0FB10Q50862164-AD69F3DA-412E-46F3-A8A0-8676C6CDE378Q55401609-EE82AD68-9B24-4472-966F-E94CA23E0018
P2860
Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@en
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@nl
type
label
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@en
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@nl
prefLabel
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@en
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@nl
P2093
P2860
P356
P1476
Modulation of very low density ...... ein E3-Leiden transgenic mice.
@en
P2093
Havekes LM
van 't Hof HB
van Vlijmen BJ
van der Boom H
van der Zee A
P2860
P304
P356
10.1172/JCI118532
P407
P577
1996-03-01T00:00:00Z